## In the Claims

1(Original). A compound of formula (I):

(I)

wherein X and Y are each CR1 or N;

one of  $R^{10}$  and  $R^{11}$  is  $R^{1}$  and the other is W;


each  $R^1$  is hydrogen, halogen, hydroxy, cyano, amino,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy, halo $C_{1-4}$ alkyl or halo $C_{1-4}$ alkoxy;

W is a phenyl ring or a six-membered heteroaromatic ring containing one, two or three nitrogen atoms, which ring is optionally substituted by halogen, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, cyano, nitro, amino, C<sub>1-6</sub>alkylamino, di(C<sub>1-6</sub>alkyl)amino, haloC<sub>1-6</sub>alkyl, haloC<sub>1-6</sub>alkoxy, carboxy, hydroxyC<sub>1-6</sub>alkyl or aminoC<sub>1-6</sub>alkyl; and

Z is a phenyl ring or a six-membered heteroaromatic ring containing one, two or three nitrogen atoms, which ring is substituted at least at the position *para* to the attachment of the ring to the rest of the molecule by halogen, C<sub>1</sub>-6alkyl, C<sub>2</sub>-6alkenyl, C<sub>2</sub>-6alkynyl, C<sub>1</sub>-6alkoxy, cyano, nitro, amino, C<sub>1</sub>-6alkylamino, di(C<sub>1</sub>-6alkyl)amino, haloC<sub>1</sub>-6alkyl, haloC<sub>1</sub>-6alkoxy, carboxy, hydroxyC<sub>1</sub>-6alkyl or aminoC<sub>1</sub>-6alkyl;

or a pharmaceutically acceptable salt thereof.

2(Original). A compound of claim 1 represented by formula (IA);



(IA)

wherein W is phenyl or pyridyl optionally substituted by halogen,  $C_{1\cdot 2}$ alkyl,  $C_{1\cdot 2}$ alkoxy, halo $C_{1\cdot 2}$ alkyl or halo $C_{1\cdot 2}$ alkoxy; and

Z is phenyl or pyridyl substituted at the position *para* to the point of attachment to the rest of the molecule by halogen,  $C_{1\cdot 2}$ alkyl,  $C_{1\cdot 2}$ alkoxy, halo $C_{1\cdot 2}$ alkyl or halo $C_{1\cdot 2}$ alkoxy;

or a pharmaceutically acceptable salt thereof.

3(Original). A compound selected from:

1,2-dihydro-2-(4-trifluoromethylphenyl)-6-(3-trifluoromethyl-2-pyridinyl)-3H-indazol-3-one;

1,2-dihydro-6-(3-methyl-2-pyridinyl)-2-(4-trifluoromethylphenyl)-3H-indazol-3-one;

1,2-dihydro-2-(4-trifluoromethylphenyl)-5-(3-trifluoromethyl-2-pyridinyl)-3H-indazol-3-one;

1,2-dihydro-6-(2-methoxyphenyl)-2-(4-trifluoromethylphenyl)-3H-indazol-3-one; and

 $1, 2\hbox{-}dihydro\hbox{-}6\hbox{-}(3\hbox{-}methyl\hbox{-}2\hbox{-}pyridinyl)\hbox{-}2\hbox{-}(4\hbox{-}trifluoromethylphenyl)\hbox{-}3H\hbox{-}pyrazolo$ 

[3,4-b]pyridin-3-one;

or a pharmaceutically acceptable salt thereof.

4(Currently Amended). A pharmaceutical composition comprising <u>a</u> one or more compounds of <del>any one of claims 1-3</del>, or pharmaceutically acceptable salts thereof in association with a pharmaceutically acceptable carrier or excipient.

5(Currently Amended). A compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, for use in treatment of the human or animal body A method for treating for or preventing of a disease or condition in

which pain and/or inflammation predominates comprising administering a compound of claim 1, or a composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof.

- 6. Cancel.
- 7. Cancel.
- 8. Cancel.
- 9. Cancel.
- 10. Cancel.